Drugs / adenovirus RSV-TK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00005057 | Mar 2000 → ? | cutaneous melanoma | National Human Genome Research Institute (NHGRI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adenovirus RSV-TK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005057 ↗ |
| Known as | AdV.RSV-TK | “A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of...” NCT00005057 ↗ |
| Route | Other | “intratumoral injection of adenovirus RSV-TK” NCT00005057 ↗ |